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Objectives: Although positron emission tomography (PET) using
18F-fluorodeoxy-glucose (FDG) frequently gives false-negative re-
sults for slow-growing tumors, 11C-acetate (AC)-PET has been
reported to be able to detect them. To determine the usefulness of
AC-PET for imaging non-small cell lung cancers (NSCLCs), the
sensitivity and specificity were compared between the AC-PET and
FDG-PET with a multicenter study.
Materials and Methods: A total of 284 pulmonary lesions (227
NSCLCs and 57 benign lesions) were examined using both AC-PET
and FDG-PET before surgery at seven Japanese institutes. The AC-
or FDG-uptake in each lesion were quantitatively measured using
the contrast ratio of the standard uptake value between the lesions
and the contralateral lung.
Results: The sensitivity of AC-PET for diagnosing NSCLC was
0.71, which was significantly higher than the value of 0.57
obtained by FDG-PET (p  0.001). No significant difference in
the specificity was seen between AC- and FDG-PET. For the 146
well-differentiated adenocarcinomas, the sensitivity of AC-PET
was 0.62, which was significantly higher than the value of 0.37
obtained by FDG-PET (p  0.001). Of the 51 moderately- or
poorly-differentiated adenocarcinomas and 30 nonadenocarcino-
mas, there was no significant difference of sensitivity between
AC- and FDG-PET.
Conclusions: AC-PET could be used in place of FDG-PET for
imaging NSCLC, with higher sensitivity for well-differentiated
adenocarcinoma compared with FDG-PET.
Key Words: Positron emission tomography, Acetate, Fluorodeoxy-
glucose, Non-small cell lung cancer, Lung adenocarcinoma.
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Recent advances in positron emission tomography (PET)using 18F-fluorodeoxy-glucose (FDG) have contributed
significantly to the ability to differentiate between non-small
cell lung cancer (NSCLC) and benign pulmonary nodules.
Nevertheless, FDG-PET sometimes gives false-negative re-
sults, particularly for well-differentiated (W/D) adenocarci-
noma because of their low glucose metabolism.1–4 We pre-
viously reported that 60% of W/D adenocarcinomas less than
3 cm in size failed to be identified by FDG-PET.2 Therefore,
other PET tracers should be used for the imaging of W/D
adenocarcinoma of the lung.
Radio-labeled acetate (AC) has long been used to
examine lipid and cholesterol synthesis in biochemistry.5,6
Clinically, 11C-AC has been widely used as a PET tracer to
evaluate myocardial oxidative metabolism.7,8 Recently,
11C-AC has also been reported to be a useful PET tracer
for imaging of slow-growing tumors that cannot be visu-
alized by FDG-PET, such as W/D hepatocellular carci-
noma, prostate cancers, and thymoma.9–11 We previously
reported that AC-PET was able to image 8 of 22 (36%) W/D
adenocarcinomas that could not be visualized by FDG-PET.12
In the present study, to examine the diagnostic usefulness of
AC-PET for NSCLC, the sensitivity and specificity for the
discrimination between NSCLC and benign nodules were
compared between the AC-PET and FDG-PET in patients
with NSCLC recruited with a multicenter study.
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MATERIALS AND METHODS
Eligibility
The study protocol was to perform AC-PET and FDG-
PET in patients with lung adenocarcinomas or lesions sus-
pected of lung adenocarcinomas before surgery. The study
was approved by the ethical committee of each of the seven
institutes involved in the study (see Appendix). Informed
consent was obtained from all patients after a discussion of
the risks and benefits of the study with their surgeons.
Patients
Between April 2005 and December 2007, a total of 248
patients with 284 pulmonary lesions larger than 1 cm in size,
who were suspected of or diagnosed as having lung adeno-
carcinomas, prospectively underwent both AC-PET and
FDG-PET before surgery. The final diagnosis of the 284
lesions were NSCLC in 227 and benign nodules in 57 (Table
1). The histologic types of the 227 NSCLCs were W/D
adenocarcinoma in 146 lesions, moderately-differentiated
(M/D) or poorly-differentiated (P/D) adenocarcinomas in 51,
and nonadenocarcinomas in 30. The histologic types of the 30
nonadenocarcinomas were squamous cell carcinoma in 27,
adenosquamous carcinoma in 2, and large cell carcinoma in
1. Of the 57 benign nodules, 20 were acute inflammations, 32
were old inflammations, and the remaining 4 were benign
tumors. The 32 old inflammatory lesions were incidentally
found away from lung cancers and were diagnosed clinically
as old inflammations without histologic examination based on
the following reasons: (1) a review of retrospective chest
radiograph or computed tomography (CT) examinations per-
formed before surgery (mean observation period, 41  23
months; range, 24–97 months) revealed that the sizes of the
lesions had remained unchanged, and (2) postoperative fol-
low-up CT examinations showed that the sizes of the lesions
had remained unchanged for more than 12 months (mean
follow-up period, 16  2 months; range, 12–20 months).
Therefore, the sizes of the 32 old inflammatory nodules had
remained unchanged for more than 36 months throughout the
preoperative and postoperative periods. The other 18 acute
inflammatory lesions, 4 benign tumors, and 227 NSCLCs
were histologically diagnosed using the resected specimens.
Preparing of 11C-Acetate
11C-AC was prepared according to the method reported
by Ishiwata et al.,13 which was based on the guidelines for
synthesis and quality control of PET tracer by the Japanese
Isotope Association. Production of AC was carried out by
using a 11C multipurpose synthesizer at the two PET centers,
i.e., C-11-BII (Sumitomo Heavy Industries Ltd., Tokyo) at
Nishidai Clinic in Tokyo and AMMC-05 (JFE Engineering
Corporation, Tokyo) at Japanese Red Cross Kumamoto
Health Care Center in Kumamoto, Japan.
PET Scanning
PET scanning was performed at Nishidai Clinic and
Japanese Red Cross Kumamoto Health Care Center by using
a POSICAM.HZL mPOWER scanner (Positron Co., Hous-
ton, TX) and an Advance Nx (GE Medical Systems, United
Kingdom), respectively. The PET parameters in the former
were as follows: transmission scan, 1 minute/bed; emission
scan, 2 minutes/bed; bed positions, eight beds; and field of
view, 16.2 cm in z axis with 12 cm in overlap. Those
parameters in the latter were as follows: emission scan, 3
minutes/bed; bed position, eight beds; and field of view, 15.7
cm in z axis with 12 cm in overlap. The AC- and FDG-PET
examinations were performed on the same day within 1
month before surgery, according to a previously reported
protocol.12 Briefly,11C-AC at a dose of 125 Ci/kg (4.6
MBq/kg) was administered first. PET imaging was performed
approximately 10 minutes after the administration of 11C-AC.
Approximately 60 minutes after AC-PET imaging,18F-FDG
at a dose of 125 Ci/kg (4.6 MBq/kg) was administered,
ensuring a gap of at least 120 minutes between the adminis-
tration of 11C-AC and that of 18F-FDG, i.e., more than six
decay half-lives of 11C (20 minutes). FDG-PET imaging was
performed approximately 60 minutes after the administration
of FDG. It took approximately 3 hours in total to examine
both AC- and FDG-PET.
PET Data Analysis
PET images were reviewed by each one radiologist at
the two PET centers (Uno and Nakashima with respective 34
and 20 years of experience for diagnosing radioisotope
scintigraphy and PET). After image reconstruction, a two-
dimensional circular region of interest (ROI) (1.0 –6.9 cm
in diameter) was drawn surrounding the lesions with pos-
itive findings. For the lesions with negative and faintly
positive PET findings, the ROI was drawn on the fusion
image with the corresponding CT to measure their standard
uptake value (SUV). The AC- and FDG-uptake were
calculated by the contrast ratio of SUV (SUV-CR) between
the lesion and the contralateral lung, as described previ-
ously.2,3 Briefly, the values of maximum SUV (SUV-max)
in the tumor ROI (T) and in the corresponding point of
contralateral normal lung ROI (N) were then measured. The
SUV-CR was calculated according to the formula of T/N for
each lesion as an index of AC or FDG uptake.
TABLE 1. Characteristics of Pulmonary Nodules
Non-small cell lung cancer (n  227)
Mean size (range) (cm) 2.0  1.0 (1.0–6.0)
Histologic subtype
W/D adenocarcinoma 146
M/D or P/D adenocarcinoma 51
Nonadenocarcinoma 30
Benign nodules (n  57)
Mean size (range) (cm) 1.7  1.2 (1.0–6.9)
Histologic type
Active inflammation 20
Old inflammation 32
Benign tumor 5
W/D, well-differentiated; M/D, moderately-differentiated; P/D, poorly-differ-
entiated.
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Pathologic Diagnosis by Central Review
Unstained slide glasses were obtained in all cases and
processed by routine hematoxylin and eosin staining and
Elastica-van Gieson staining. The histologic sections were
reviewed by two pathologists at Kumamoto University Hos-
pital (Iyama and Honda with 34 and 22 years, respectively, of
experience making pathologic diagnoses), who were unaware
of the patients’ clinical data. The histologic types of NSCLC
were classified according to the World Health Organization
classification.14,15 A consensus was reached if any difference
in their opinions existed.
Determining the Cutoff Values of SUV-CR
The cutoff values for discrimination between NSCLC
and benign nodules were determined using a receiver oper-
ating characteristics (ROC) curve that was constructed using
SPSS software (SPSS 15.0 J for Windows, SPSS, Chicago,
IL). The value with the highest sensitivity and the highest
specificity was determined as the cutoff value on the ROC
curve. Lesions with higher SUV-CR than cutoff value were
defined as positive on AC- or FDG-PET result.
Statistical Analysis
The true-positive (TP), true-negative (TN), false-posi-
tive (FP), and false-negative (FN) results of the AC- and
FDG-PET images were compared with the pathologic diag-
noses. Sensitivity was calculated as TP/TP  FN and spec-
ificity as TN/TN  FP; differences between the AC- and
FDG-PET results were analyzed using the McNemar test.
The differences in the positive rates among the histologic
types were analyzed using a 2 test. The differences in
SUV-CR values among the histologic subtypes of NSCLC
were analyzed using the Fisher’s exact test. These statistical
analyses were performed using the SPSS software. Values of
p less than 0.05 were considered significant. All values in the
text and tables are given as the mean  SD.
RESULTS
AC-PET usually identified W/D adenocarcinomas
more clearly than FDG-PET (Figure 1). AC-PET also iden-
tified other types of NSCLC and FDG-PET (Figure 2). The
ROC curve for the discrimination between NSCLC and
benign nodules showed the optimal SUV-CR cutoff value to
be 1.35 for AC-PET and 1.66 for FDG-PET (Figure 3).
Table 2 shows the correlation between AC- and FDG-
PET for the diagnosis of NSCLC. The sensitivity of AC-PET
was 0.71 (95% confidence interval CI: 0.65–0.77), which
was significantly higher than the value of 0.57 (95% CI:
FIGURE 1. Well-differentiated adenocarcinoma with
ground-glass opacity findings. A, Computed tomographic
findings. B, 18F-fluorodeoxy-glucose-positron emission to-
mography showed negative. C, 11C-acetate-positron emis-
sion tomography showed positive. An arrow shows the im-
age of tumor.
FIGURE 2. Squamous cell carcinoma. A,
Computed tomographic findings. B, 18F-
fluorodeoxy-glucose-positron emission
tomography showed positive. C, 11C-
acetate-positron emission tomography
showed positive. An arrow shows the
image of tumor.
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0.51–0.63) obtained by FDG-PET (McNemar test: p 
0.001). Table 3 shows the correlation between AC- and
FDG-PET for the diagnosis of benign nodules. The specific-
ities of AC- and FDG-PET were 0.70 (95% CI: 0.58–0.82)
and 0.77 (95% CI: 0.66–0.88), respectively; this difference
was not significant (McNemar test: p  0.29).
Table 4 shows the AC- and FDG-PET findings in each
histologic type of NSCLC. For the 146 W/D adenocarcino-
mas, the sensitivity of AC-PET was 0.62, which was signif-
icantly higher than the value of 0.37 obtained by FDG-PET
(McNemar test: p  0.001). For the 51 M/D or P/D adeno-
carcinomas, the sensitivities of AC- and FDG-PET were 0.84
and 0.90, respectively; this difference was not significant
FIGURE 3. The receiver operating characteristics curve of
contrast ratio of standard uptake value (SUV-CR) for diag-
nosing non-small cell lung cancer. A, Acetate-positron emis-
sion tomography. Cutoff value of SUV-CR is 1.35 (sensitivity:
0.69, 1-specificity: 0.37, area under curve: 0.65, 95% confi-
dence interval: 0.57–0.73). B, 18F-fluorodeoxy-glucose-
positron emission tomography. Cutoff value of SUV-CR is
1.66 (sensitivity: 0.57, 1-specificity: 0.19, area under curve:
0.62, 95% confidence interval: 0.55–0.70).
TABLE 2. Correlation between Acetate-PET and FDG-PET
for Diagnosis of Non-small Cell Lung Cancer
FDG-PET
Acetate-PET
True-positive False-negative Total
True-positive 114 15 129
False-negative 47 51 98
Total 161 66 227
FDG, fluorodeoxyglucose; PET, positron emission tomography.
Sensitivity of acetate-PET: 0.71 (95% confidence interval: 0.65–0.77).
Sensitivity of FDG-PET: 0.57 (95% confidence interval: 0.51–0.63).
McNemar test: p  0.001.
TABLE 3. Correlation between Acetate-PET and FDG-PET
for Diagnosis of Benign Pulmonary Nodules
FDG-PET
Acetate-PET
True-negative False-positive Total
True-negative 38 6 44
False-positive 2 11 13
Total 40 17 57
FDG, fluorodeoxyglucose; PET, positron emission tomography.
Specificity of acetate-PET: 0.70 (95% confidence interval: 0.58–0.82).
Specificity of FDG-PET: 0.77 (95% confidence interval: 0.66–0.88).
McNemar test: p  0.29.
TABLE 4. Correlation between Acetate-PET and FDG-PET
for Diagnosis of Each Histologic Type of Non-small Cell Lung
Cancer
FDG-PET
Acetate-PET
True-positive False-negative Difference
W/D adenocarcinoma
(n  146)
True-positive 47 7
False-negative 43 49 p  0.001
M/D or P/D
adenocarcinoma
(n  51)
True-positive 39 7
False-negative 4 1 p  0.55
Nonadenocarcinoma
(n  30)
True-positive 28 1
False-negative 0 1 p  1.0
FDG, fluorodeoxyglucose; PET, positron emission tomography; W/D, well-differ-
entiated; M/D, moderately-differentiated; P/D, poorly-differentiated.
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(McNemar test: p  0.55). For the 30 nonadenocarcinomas,
the sensitivities of AC- and FDG-PET were 0.93 and 0.97,
respectively; this difference was not significant (McNemar
test: p  1.0). In the AC-PET, the positive rates for W/D
adenocarcinoma (62%) was significantly lower than those for
M/D or P/D adenocarcinomas (86%) and nonadenocarcino-
mas (93%) (p  0.003 and 0.001, respectively). In the
FDG-PET, the positive rates for W/D adenocarcinomas
(37%) was significantly lower than those for M/D or P/D
adenocarcinomas (90%) and nonadenocarcinomas (97%)
(both, p  0.001).
Figure 4 shows the distribution of the SUV-CR values
for AC-PET and FDG-PET according to each histologic type.
The mean SUV-CR values for W/D adenocarcinomas, M/D
or P/D adenocarcinomas, and nonadenocarcinomas obtained
by AC-PET were 1.7  1.1, 2.0  0.8, and 3.8  2.7,
respectively (Figure 4A), whereas those obtained by FDG-
PET were 2.1  2.0, 4.5  3.2, and 16  20, respectively
(Figure 4B). M/D or P/D adenocarcinomas and nonadenocar-
cinomas had a significantly higher SUV-CR values than W/D
adenocarcinomas in both the AC-PET (p  0.025 and p 
0.001, respectively) and FDG-PET (both p  0.001). Non-
adenocarcinomas also had a significantly higher SUV-CR
value than M/D or P/D adenocarcinoma in both the AC- and
FDG-PET (p  0.002 and 0.003, respectively).
DISCUSSION
The present study showed that AC-PET had significantly
higher sensitivity for diagnosing W/D adenocarcinomas than
FDG-PET, whereas there was no significant difference of sen-
sitivity for diagnosing M/D or P/D adenocarcinomas and non-
adenocarcinomas between the two. There was no significant
difference of specificity between the two. We therefore con-
cluded that AC-PET can be used in place of FDG-PET for the
imaging NSCLC, with higher sensitivity for W/D adenocarci-
nomas.
Although the mechanism underlying 11C-AC-uptake in
tumor cells has not been clarified sufficiently, Yoshimoto et
al.,16 in an in vitro study using several cancer cell lines,
reported that the 14C-AC level in the lipid-soluble fraction of
the tumor cells was positively correlated with the tumor
growth activity measured by 3H-thymidine uptake; therefore,
they suggested that AC was preferentially metabolized to
membrane lipids in tumor cells and that AC-uptake by the
tumor cells reflects their growth activity, which could be
paralleled to the enhanced membrane synthesis. On the other
hand, AC-PET has been reported to be able to image slow-
growing tumors, such as W/D hepatocellular carcinoma,
prostate cancer, and thymoma, which often show negative
imaging with FDG-PET.9–11 In the present study, although
the W/D adenocarcinomas could be imaged by AC-PET more
frequently than by FDG-PET, they showed less positive rates
and less SUV-CR values than M/D or P/D adenocarcinomas
or nonadenocarcinomas in both the AC- and FDG-PET.
Based on these data, we have made the following hypoth-
eses explaining AC- and FDG-uptake in NSCLC: (1)
whereas FDG would hardly accumulate in W/D adenocar-
cinomas because of their low glucose metabolism, AC
might accumulate in them, probably because they metab-
olize AC for membrane lipid synthesis; and (2) aggressive
adenocarcinomas like M/D or P/D adenocarcinomas and
nonadenocarcinomas would metabolize both AC and FDG
actively for both membrane lipid synthesis and glucose
metabolism, respectively.
Although SUV-max has frequently been used to
evaluate FDG-PET, several factors have been reported to
FIGURE 4. Distribution of SUV-CR for (A) 11C-acetate-
positron emission tomography and (B) 18F-fluorodeoxy-glu-
cose-positron emission tomography among each histologic
types of non-small cell lung cancer. SUV-CR, contrast ratio of
standard uptake value.
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affect the SUV-max, such as body size17 and blood glucose
level.18,19 We previously compared the results of SUV-max,
SUV-CR with the contralateral lung, and SUV-CR with the
cerebellum for pulmonary nodules, and reported that the
SUV-CR with contralateral lung or cerebellum was signifi-
cantly more sensitive than the SUV-max4; this result was
further supported in a study by Obrzut et al.20 Besides,
because two kinds of PET scans were used in the present
study, we used the SUV-CR with the contralateral lung to
dissolve the possible difference of SUV measurement be-
tween the two PET scans.
The area under the curve on ROC curve obtained by
FDG-PET in the present study was not large enough, com-
pared with our previously reported one,2 that would be likely
attributable to the followings: Because the purpose of the
present study was to compare the sensitivity and specificity
between AC- and FDG-PET in patients with lung adenocar-
cinoma or lesions suspected of lung adenocarcinoma, 146 of
the 229 (64%) adenocarcinomas were W/D adenocarcinomas
that produced negative FDG-PET results more frequently
than other histologic types of NSCLC, resulting in a small
area under the curve on the ROC curve.
The present study showed that AC-PET was superior to
FDG-PET for the imaging of W/D adenocarcinomas and was
equal with FDG-PET for the imaging of other histologic
types of NSCLC. AC-PET has the following advantages
over FDG-PET: (1) patients do not have to fast before
examination; (2) radiation exposure from 11C-AC is less
than that from 18F-FDG because the half life is much
shorter (20 minutes versus 120 minutes); and (3) less time
is required for the examination (20 minutes for AC-PET
versus 90 minutes for FDG-PET). We therefore consider
that AC-PET can be used in place of FDG-PET for
imaging NSCLC, with higher sensitivity for W/D adeno-
carcinomas compared with FDG-PET.
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